Although KIT activating mutations have been found to drive transformation in GIST, acute myeloid leukemia, mast cell leukemia, and melanoma, no gain-of-function mutations on KIT have been reported in neuroblastoma [108] [109]. This evidence concerns the gene KIT and melanoma.